| Literature DB >> 33808219 |
Abstract
Biomimetic (non-cell based in vitro) and computational (in silico) studies are commonly used as screening tests in laboratory practice in the first stages of an experiment on biologically active compounds (potential drugs) and constitute an important step in the research on the drug design process. The main aim of this study was to evaluate the ability of triterpenoid saponins of plant origin to cross the blood-brain barrier (BBB) using both computational methods, including QSAR methodology, and biomimetic chromatographic methods, i.e., High Performance Liquid Chromatography (HPLC) with Immobilized Artificial Membrane (IAM) and cholesterol (CHOL) stationary phases, as well as Bio-partitioning Micellar Chromatography (BMC). The tested compounds were as follows: arjunic acid (Terminalia arjuna), akebia saponin D (Akebia quinata), bacoside A (Bacopa monnieri) and platycodin D (Platycodon grandiflorum). The pharmacokinetic BBB parameters calculated in silico show that three of the four substances, i.e., arjunic acid, akebia saponin D, and bacoside A exhibit similar values of brain/plasma equilibration rate expressed as logPSFubrain (the average logPSFubrain: -5.03), whereas the logPSFubrain value for platycodin D is -9.0. Platycodin D also shows the highest value of the unbound fraction in the brain obtained using the examined compounds (0.98). In these studies, it was found out for the first time that the logarithm of the analyte-micelle association constant (logKMA) calculated based on Foley's equation can describe the passage of substances through the BBB. The most similar logBB values were obtained for hydrophilic platycodin D, applying both biomimetic and computational methods. All of the obtained logBB values and physicochemical parameters of the molecule indicate that platycodin D does not cross the BBB (the average logBB: -1.681), even though the in silico estimated value of the fraction unbound in plasma is relatively high (0.52). As far as it is known, this is the first paper that shows the applicability of biomimetic chromatographic methods in predicting the penetration of triterpenoid saponins through the BBB.Entities:
Keywords: IAM stationary phase; Quantitative Structure-Activity Relationship (QSAR); biomimetic studies; computational studies; micellar liquid chromatography; triterpenoid saponins
Mesh:
Substances:
Year: 2021 PMID: 33808219 PMCID: PMC8037809 DOI: 10.3390/ijms22073573
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
The use of Bio-partitioning Micellar Chromatography (BMC), Immobilized Artificial Membrane (IAM), and cholesterol (CHOL) chromatography to evaluate the biological activity of organic compounds.
| References | Drugs | BMC/IAM System | Biological Activity |
|---|---|---|---|
| [ | Anticonvulsant drugs | Brij 35: 0.02 M; 0.04 M; 0.06 M; pH: 7.4 | Anticonvulsant properties |
| [ | Non-steroidal anti-inflammatory drugs | Brij 35: 0.02 M; 0.04 M; 0.06 M; pH: 7.4 | Anesthetic potency |
| [ | Local anesthetics | Brij 35: 0.02 M; 0.04 M; 0.06 M; pH: 7.4 | Anesthetic potency |
| [ | Barbiturates | Brij35: 0.02 M; 0.04 M; 0.06 M | Hypnotic activity |
| [ | Catecholamines | SDS: 0.05 M; 0.1 M + MeOH, EtOH, 1-propanol, pentanol | β- andrenergic activity |
| [ | Benzodiazepines | Brij35: 0.02 M; 0.04 M; 0.06 M | Toxicity and anxiolytic activity |
| [ | Phenothiazines | Brij35: 0.02 M; 0.04 M; 0.06 M | Pharmacokinetics, preclinical pharmacology, and therapeutic efficacy parameters; antipsychotic potential |
| [ | Structurally diverse drugs | Brij35: 0.04 M | Oral absorption |
| [ | Fatty acids and polyphenols | Brij35: 0.04 M; 0.06 M; 0.08 M; 0.1 M; 0.12 M + acetonitrile | Oral, jejunum and Caco-2 absorption |
| [ | Structurally diverse drugs | Brij35: 0.04 M | BBB permeability |
| [ | Phenols | Brij35: 0.06 M; 0.08 M; 0.1 M; 0.12 M + isobutanol (5% | BBB permeability |
| [ | Non-steroidal anti-inflammatory drugs | Brij35: 0.04 M | Skin permeability |
| [ | Fatty acids and polyphenols | Brij35: 0.04 M; 0.06 M; 0.08 M; 0.1 M; 0.12 M + acetonitrile | Percutaneous absorption |
| [ | Anxiolytics, antihistamines, β-blockers, antiepileptics, antipsychotics | SDS: 0.07 M; 0.09 M | Protein drug binding properties |
| [ | Structurally diverse drugs | PBS or PBS-acetonitrile: 5–25% | Cell permeability, human oral absorption, % plasma protein binding |
| [ | Novel β-hydroxy-β-aryl-alkanoic acids | Brij35: 0.04 M | Gastrointestinal absorption |
| [ | Structurally diverse drugs | Brij35: 0.04 M | Blood to lung; blood to liver; blood to fat; blood to skin partition coefficients |
| [ | Newly-synthesized 17-β-carboxamide steroids | Brij35: 0.04 M | Skin and corneal permeability |
| [ | Structurally diverse drugs | Brij35: 0.04 M | Ocular tissue permeability |
| [ | Structurally diverse drugs | Brij35: 0.04 M | BBB permeability |
| [ | Benzophenone ultraviolet filters | Brij35: 0.01 M; 0.02 M; 0.03 M | Ecotoxicity and skin permeability |
| [ | Structurally diverse pesticides | Phosphate-buffered saline (PBS) or PBS-acetonitrile: 5–25% | Ecotoxicity |
| [ | Structurally diverse compounds | Buffer- MeOH: 70:30 | BBB permeability |
| [ | Structurally diverse drugs | PBS or PBS-acetonitrile: 5–25% | Bioconcentration factor |
| [ | Structurally diverse drugs | Acetonitrile-buffer | Interactions between the solutes and the immobilized phospholipid membranes |
| [ | Structurally diverse drugs | Acetonitrile-buffer: 0–30% | Human oral absorption |
| [ | Newly-synthesized drug-like compounds | Acetonitrile-buffer | Blood–brain barrier permeation |
| [ | Newly synthesized antiproliferative and analgesic active compounds | Acetonitrile-buffer | Lipophilicity |
The chemical structures of the tested compounds.
| Name | Structure |
|---|---|
| Arjunic acid |
|
| Akebia saponin D |
|
| Bacoside A |
|
| Platycodin D |
|
The pharmacokinetic BBB descriptors calculated in silico (ACD/Percepta).
| Name | logBB | logPS | logPSFubrain | Fu | Fb |
|---|---|---|---|---|---|
| Arjunic acid | 0.14 | −3.2 | −4.9 | 0.012 | 0.02 |
| Akebia saponin D | 0.32 | −4.4 | −5.7 | 0.12 | 0.06 |
| Bacoside A | 0.03 | −3.6 | −4.5 | 0.14 | 0.13 |
| Platycodin D | <−2 | −3.6 | −9.0 | 0.52 | 0.98 |
logBB, Blood–brain barrier penetration descriptor; logPS, Logarithmic permeability–surface areaproduct; log(PSFubrain), Brain/plasma equilibration rate; Fu, Fraction unbound in plasma; Fb, Fraction unbound in the brain.
The chosen physicochemical parameters determined for the tested saponins.
| Name | LogPow (Octanol/Water) | logPhw (Heptane/Hater) | logPcw (Cyclohexane /Water) | Molecular Weight (MW) (g/mol) | Topological Polar Surface Area (TPSA) (Å2) | Polarizability |
|---|---|---|---|---|---|---|
| Arjunic acid | 5.2 | 4.179 | 4.029 | 488.70 | 97.99 | 54.15 |
| Akebia saponin D | 0.8 | −9.919 | −9.932 | 929.10 | 294.98 | 91.23 |
| Bacoside A | 2.8 | −7.553 | −7.110 | 768.97 | 215.83 | 78.66 |
| Platycodin D | −3.7 | −24.512 | −24.704 | 1225.32 | 453.28 | 114.32 |
Figure 1Logkw-BMC, logkw-IAM, and logkw-CHOL values obtained from the tested systems.
Figure 2LogBB values obtained using the biomimetic and computational methods.